Neuland Laboratories Limited
All news and filings related to Neuland Laboratories Limited.
View all news & filings- Medium impact
Neuland Labs Approves ₹126 Crore Land Purchase for Future Expansion
Neuland Laboratories approved a capital expenditure of ₹126 crores for acquiring 134 acres of land in Kakinada, Andhra Pradesh. This land is intended for future expansion and will be funded through internal accruals. The company also has an option to acquire an additional 66 acres.
Read the summary - Medium impact
Neuland Labs: CRISIL Affirms A+/A1 Ratings, Revises Outlook to Positive
Crisil Ratings has reaffirmed Neuland Laboratories Limited's credit ratings. The long-term rating is CRISIL A+/Positive, with the outlook revised to 'Positive'. The short-term rating is CRISIL A1. This announcement was made on August 25, 2026.
Read the summary - Low impact
Neuland Labs: Special Window for Share Transfer and Dematerialization Opens
Neuland Laboratories Limited has opened a Special Window for transfer and dematerialization of physical shares. This is in line with SEBI's circular dated January 30, 2026. The announcement was published on August 22, 2026.
Read the summary - Medium impact
Neuland Labs Unit 3 Facility Receives One Observation in US FDA Inspection
Neuland Laboratories' Unit 3 manufacturing facility was inspected by the US FDA from August 10-14, 2026. The inspection resulted in one observation related to procedural improvements in water and environmental monitoring. The company will respond to the FDA within the given timeframe.
Read the summary - High impact
Neuland Labs Q1FY27 Earnings Call Transcript Released
Neuland Laboratories Limited released its Q1 FY27 earnings call transcript. Total income rose 16.3% to ₹650.1 crores, with PAT at ₹147.4 crores. EBITDA was ₹231.1 crores (35.5% margin). The company expects 20% growth in FY27-FY28 and announced a strategic collaboration with Gland Pharma for sterile APIs.
Read the summary - Low impact
Neuland Labs to Participate in Emkay Confluence 2026 on Aug 12
Neuland Laboratories Limited management will attend the Emkay Confluence 2026 in Mumbai on August 12, 2026. The event includes group and one-on-one meetings with analysts and institutional investors. The schedule is subject to change.
Read the summary - Low impact
Neuland Labs Publishes Q1 FY27 Financial Results Advertisement in Newspapers
Neuland Laboratories Limited published newspaper advertisements on August 6, 2026, detailing its financial results for the quarter ending June 30, 2026. This action complies with SEBI regulations.
Read the summary - Low impact
Neuland Labs: Audio Recording of Q1 FY27 Earnings Call Available
Neuland Laboratories Limited has released the audio recording of its earnings call for the quarter ended June 30, 2026. The call took place on August 5, 2026. The recording is accessible on the company's investor relations webpage.
Read the summary - High impact
Neuland Labs Approves Q1 FY27 Results, Expands Capacity & Guarantees Gland Pharma Loan
Neuland Laboratories approved Q1 FY27 results. The company will provide a ₹40 crore corporate guarantee to Gland Pharma for a loan license agreement to establish dedicated manufacturing capacity. Additionally, Neuland will invest ₹39.8 crore to add 18 KL capacity at its Unit 1 facility, expected in 6-7 months.
Read the summary - High impact
Neuland Labs Approves Q1 FY27 Results, Guarantees ₹40 Cr for Gland Pharma, Expands Capacity
Neuland Laboratories approved Q1 FY27 results, reporting total income of ₹65,006.88 lakhs. The company approved a ₹40 crore corporate guarantee for Gland Pharma and a ₹39.8 crore investment to add 18 KL manufacturing capacity within 6-7 months. A strategic partnership with Gland Pharma was also announced to expand sterile API manufacturing with a new facility.
Read the summary - High impact
Neuland Labs Q1FY27: Income surges 116% to ₹650 Cr, PAT up 975% to ₹147 Cr
Neuland Laboratories reported a strong Q1FY27 with total income soaring 116.3% YoY to ₹650.1 crore. PAT surged 975% to ₹147.4 crore, and EBITDA grew 448.2% to ₹231.1 crore. The company invested ₹122 crore in capex and saw working capital days reduce to 84.
Read the summary - High impact
Neuland Labs Q1FY27 Income ₹650.1 Cr, EBITDA ₹231.1 Cr; CEO Optimistic on Growth
Neuland Laboratories reported Q1FY27 total income of ₹650.1 crore, up 116.3% YoY. EBITDA surged 448.2% to ₹231.1 crore, with margins at 35.5%. PAT rose 975.0% to ₹147.4 crore. CEO Saharsh Davuluri expressed optimism about growth and increasing investments. An earnings call is scheduled for August 5, 2026.
Read the summary - High impact
Neuland Labs Approves Q1 FY27 Results, Guarantees ₹40 Cr for Gland Pharma, Expands Capacity
Neuland Laboratories approved Q1 FY27 results with consolidated revenue at ₹641.58 crore and profit after tax at ₹147.67 crore. The company will provide a ₹40 crore corporate guarantee for Gland Pharma for a loan license agreement. Capacity at Unit 1 will increase by 18 KL with a ₹39.8 crore investment.
Read the summary - Medium impact
Neuland Labs AGM: Financials Adopted, Final Dividend Declared, Directors Reappointed
Neuland Laboratories Limited's 42nd AGM on August 4, 2026, saw the adoption of audited financial statements for FY26 and the declaration of a final dividend of ₹34 per share for FY26. Directors Dr. Davuluri Rama Mohan Rao and Dr. Mauricio Futran were appointed/reappointed.
Read the summary - Medium impact
Neuland Laboratories: Commercial Production Begins at Expanded Units 1 & 3
Neuland Laboratories Limited has commenced commercial production at its expanded Unit 1 and Unit 3 facilities in Telangana. This marks a significant step in the company's expansion plans, following previous intimations on August 1, 2024, and January 21, 2025.
Read the summary - Low impact
Neuland Laboratories Schedules Q1 FY27 Earnings Conference Call for August 5, 2026
Neuland Laboratories Limited will host its Q1 FY27 Earnings Conference Call on August 5, 2026, at 17:30 IST. The company invites analysts and institutional investors to discuss its financial performance.
Read the summary - Low impact
Neuland Labs: Shareholder Reports Loss of 100 Share Certificates
Neuland Laboratories Limited informed stock exchanges about a shareholder reporting the loss of 100 share certificates. The company received this information on July 20, 2026, and will issue a duplicate entitlement letter.
Read the summary - Low impact
Neuland Laboratories: India Ratings Affirms Credit Rating as IND A+/Positive/IND A1
India Ratings and Research has affirmed Neuland Laboratories Limited's credit rating for bank loan facilities as IND A+/Positive and IND A1. This affirmation was announced on July 13, 2026.
Read the summary - Low impact
Neuland Labs Announces Newspaper Publication for 42nd AGM
Neuland Laboratories Limited announced its 42nd Annual General Meeting (AGM) will be held via Video Conference. The notice of AGM and Integrated Annual Report have been dispatched electronically. Advertisements were published on July 10, 2026.
Read the summary - Low impact
Neuland Labs Schedules 42nd AGM for August 4, 2026, via VC/OAVM
Neuland Laboratories Limited will hold its 42nd Annual General Meeting on August 4, 2026, at 10:00 a.m. IST via Video Conference. The Integrated Annual Report for FY 2025-26 is also available.
Read the summary - Low impact
Neuland Labs Releases FY26 Business Responsibility and Sustainability Report
Neuland Laboratories Limited has released its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance, commitments, and strategies across environmental, social, and governance principles. It is available on the company's website and has been submitted to stock exchanges.
Read the summary - Low impact
Neuland Labs Files SEBI Compliance Certificate for Q1 FY27
Neuland Laboratories Limited submitted a compliance certificate for the quarter ended June 30, 2026, as required by SEBI regulations. The certificate confirms the details of securities dematerialized/rematerialized have been furnished to stock exchanges.
Read the summary - Low impact
Neuland Labs Announces 42nd AGM and Record Date
Neuland Laboratories Limited will hold its 42nd Annual General Meeting via Video Conference. The company has published related information, including the record date, in newspapers on June 16, 2026.
Read the summary - Low impact
Neuland Labs Management to Participate in Nuvama India Conference in London on June 8-9, 2026
Neuland Laboratories management will attend the Nuvama India Conference in London on June 8-9, 2026. The event will feature group and one-on-one meetings with analysts and institutional investors. The schedule is subject to change.
Read the summary - Low impact
Neuland Labs to Participate in BOFA Healthcare Tour on June 5
Neuland Laboratories Limited's management will attend the BOFA Healthcare Tour on June 5, 2026, in Hyderabad. The event includes group and one-on-one meetings with analysts and institutional investors.
Read the summary - Low impact
Neuland Labs Management to Participate in 360 ONE Capital Investor Conference on May 28, 2026
Neuland Laboratories Limited management will attend the 360 ONE Capital's 16th Annual Investor Conference on May 28, 2026, in Mumbai. The event will involve group and one-on-one investor meetings.
Read the summary - Medium impact
Neuland Labs Q4 FY26 Earnings Call Transcript Released
Neuland Laboratories released its Q4 FY26 earnings call transcript. Q4 revenue was ₹788.7 crore, up 134.9% YoY, with EBITDA at ₹319.4 crore. FY26 revenue grew 37.1% to ₹2053.1 crore. Free cash flow was negative ₹49.4 crore due to higher working capital. The company is investing in peptide facilities and R&D for long-term growth.
Read the summary - Low impact
Neuland Labs Announces Special Window for Physical Share Transfer & Dematerialization
Neuland Laboratories Limited has opened a Special Window for the transfer and dematerialization of physical shares. This initiative, as per SEBI guidelines, was advertised on May 15, 2026. The company is facilitating this process to streamline shareholding.
Read the summary - Low impact
Neuland Labs Publishes Financial Results for Q4FY26 in Newspapers
Neuland Laboratories Limited published its financial results for the quarter and year ended March 31, 2026, in newspapers on May 13, 2026. This compliance filing was made with BSE and NSE.
Read the summary - Low impact
Neuland Labs: Audio Recordings of Q4 FY26 Earnings Call Available
Neuland Laboratories Limited has released the audio recordings of its earnings call for the quarter and year ended March 31, 2026. The call took place on May 12, 2026, and the recordings are available on the company's investor website.
Read the summary - High impact
Neuland Labs Approves FY26 Audited Results, ₹34 Final Dividend, and Capacity Expansion
Neuland Laboratories approved audited FY26 results and recommended a final dividend of ₹34 per share. The company will expand its Unit 1 capacity by 120.5 KL over 12-18 months with a ₹143.4 crore investment. Dr. Mauricio Futran was appointed as Additional Director. The 42nd AGM is scheduled for August 4, 2026.
Read the summary - High impact
Neuland Labs FY26 Total Income ₹2,053 Crore; EBITDA ₹603 Crore
Neuland Laboratories reported FY26 total income of ₹2,053.1 crore and EBITDA of ₹603.4 crore. Q4FY26 income was ₹788.7 crore, up 134.9% YoY, with EBITDA at ₹319.4 crore, up 448.6% YoY. CEO Saharsh Davuluri noted strong business visibility and ongoing investments in Peptide Manufacturing and R&D.
Read the summary - High impact
Neuland Labs Approves FY26 Results, ₹34 Dividend, Director Appointment, and Capacity Expansion
Neuland Laboratories approved audited FY26 results, recommended a final dividend of ₹34 per share, and appointed Dr. Mauricio Futran as an Additional Director. The company will convene its 42nd AGM on August 4, 2026, and plans a capacity expansion of 120.5 KL at Unit 1 with an investment of ₹143.4 crores.
Read the summary - High impact
Neuland Labs Approves FY26 Results, Recommends Final Dividend of ₹34/Share
Neuland Laboratories approved its FY26 audited results and recommended a final dividend of ₹34 per share. Dr. Mauricio Futran was appointed as an Additional Director. The 42nd AGM is on August 4, 2026, with a record date of July 24, 2026. The company will also enhance its Unit 1 capacity with a ₹143.4 crore investment.
Read the summary - High impact
Neuland Labs Approves Final Dividend, Director Appointment, and Capacity Expansion
Neuland Laboratories approved its FY26 audited financial results. A final dividend of ₹34 per share was recommended. Dr. Mauricio Futran was appointed as an Additional Director. The company will increase capacity by 120.5 KL at Unit 1 with an investment of ₹143.4 crore. The 42nd AGM is on August 4, 2026.
Read the summary - High impact
Neuland Labs Approves FY26 Audited Results, Recommends Final Dividend of ₹34, Appoints New Director
Neuland Laboratories approved audited FY26 results with ₹2,05,315.16 lakhs income and ₹36,399.84 lakhs PAT. A final dividend of ₹34 per share was recommended. Dr. Mauricio Futran was appointed as an Additional Director. The company will invest ₹143.4 crores for capacity expansion at Unit 1.
Read the summary - High impact
Neuland Labs Q4FY26 Total Income ₹788.7 Cr, EBITDA ₹319.4 Cr
Neuland Laboratories reported Q4FY26 results with total income at ₹788.7 crore (up 134.9% YoY) and EBITDA at ₹319.4 crore (up 448.6% YoY). PAT increased to ₹212.5 crore. CEO Saharsh Davuluri expressed satisfaction with the strong performance and future growth prospects driven by investments in peptide manufacturing and R&D.
Read the summary - High impact
Neuland Labs Presents Q4FY26 Investor Presentation, Highlighting Strong Growth
Neuland Laboratories reported a strong Q4FY26 with Total Income at ₹788.7 Cr (up 134.9% YoY) and PAT at ₹212.5 Cr (up 666.3% YoY). For FY26, Total Income reached ₹2053.1 Cr (up 37.1% YoY) and PAT was ₹363.1 Cr (up 40% YoY). Management highlighted strong business visibility and strategic investments in peptide manufacturing and R&D.
Read the summary - High impact
Neuland Labs Q4FY26 Income ₹788.7 Crore, EBITDA ₹319.4 Crore
Neuland Laboratories reported Q4FY26 Total Income of ₹788.7 crore, up 134.9% YoY. EBITDA was ₹319.4 crore, a 448.6% increase. PAT rose 666.3% to ₹212.5 crore. CEO Saharsh Davuluri expressed satisfaction with the strong finish to FY26, highlighting business visibility and strategic investments.
Read the summary - High impact
Neuland Labs Approves Final Dividend, Capacity Expansion, and Appoints New Director
Neuland Laboratories approved a final dividend of ₹34 per share for FY26. The company will expand its Unit 1 capacity by 120.5 KL with a ₹143.4 crore investment. Dr. Mauricio Futran was appointed as an Additional Director. The 42nd AGM is scheduled for August 4, 2026.
Read the summary - High impact
Neuland Labs Approves ₹143 Cr Capex, Recommends ₹34 Dividend, Appoints New Director
Neuland Laboratories approved audited financial results for FY26 and recommended a final dividend of ₹34 per share. Dr. Mauricio Futran was appointed as Additional Director. The company will invest ₹143.4 crores in capacity expansion. The 42nd AGM is on August 4, 2026.
Read the summary - Medium impact
Neuland Labs Announces Q4 FY26 Earnings Call for May 12, 2026
Neuland Laboratories Limited will announce its Q4 and full-year FY26 results on May 12, 2026. The company will host an Earnings Call on the same day at 17:30 IST to discuss the financial performance. The results will be available on the company website.
Read the summary - Low impact
Neuland Labs Publishes Notice for Unclaimed Dividend Transfer to IEPF
Neuland Laboratories Limited is transferring unclaimed dividends and shares to the IEPF as per the Companies Act, 2013. A notice was published on April 21, 2026. The company may increase its board from 9 to 11 directors and has secured a new order. A new CFO has been appointed.
Read the summary - Low impact
Neuland Labs Publishes Newspaper Ad for Investor Campaign
Neuland Laboratories Limited has launched its Second 100 Days Campaign, "Saksham Niveshak," running from April 1, 2026, to July 9, 2026. The announcement was published in newspapers on April 14, 2026.
Read the summary - Low impact
Neuland Labs: Davuluri Ownership Trust Files Compliance Certificate for FY26
Davuluri Ownership Trust has submitted its annual compliance certificate for FY26. The certificate, issued by B Srinivasa Rao & Co., confirms compliance with SEBI Exemption Order and SAST Regulations. This filing relates to substantial acquisition of shares and takeovers.
Read the summary - Low impact
Neuland Labs: Certificate Under SEBI Reg. 74(5) For Q4FY26 Filed
Neuland Laboratories Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The company's Registrar and Share Transfer Agent, Kfin Technologies Limited, confirmed that dematerialization/rematerialization details were submitted to stock exchanges and depositories.
Read the summary - Medium impact
Saharsh Davuluri Appointed CEO & MD of Neuland Laboratories
Saharsh Davuluri has been appointed CEO & MD of Neuland Laboratories, effective immediately, succeeding Sucheth Davuluri who becomes Executive Vice Chairman. The company aims to accelerate CDMO growth, expand commercial peptide capacity, and double process development capabilities. Neuland anticipates securing more commercial NCE contracts in the next 1-2 years.
Read the summary - Low impact
Neuland Labs: Trading Window Closed from April 1 for Q4FY26 Results
Neuland Laboratories Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. The date of the board meeting for results declaration will be announced later.
Read the summary - Low impact
Neuland Laboratories: Issues Letter of Confirmation for Lost Share Certificates
Neuland Laboratories will issue a Letter of Confirmation for 100 shares reported lost by shareholder RAJESH KHANDWALA. This follows SEBI regulations for lost share certificates.
Read the summary - Low impact
Neuland Labs: Shareholder Reports Loss of 100 Shares
Neuland Laboratories Limited announced that shareholder Rajesh Khandwala reported the loss of 100 share certificates. The company received this information on March 12, 2026, and will issue a 'Letter of Confirmation'.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio